Austedo Reviews & Ratings - Drugs.com
Austedo User Reviews & Ratings Austedo has an average rating of 6.9 out of 10 from a total of 14 reviews on Drugs.com. 57% of reviewers reported a positive experience, while 14% reported a …
Austedo Phase 4 Data Shows Reduction in Tardive Dyskinesia …
Nov 12, 2025 · Austedo standard and XR tablets are currently indicated for adults for the treatment of chorea in Huntington disease and tardive dyskinesia. Austedo is the first VMAT2 …
Teva Pharmaceuticals Reports Positive Real-World Data on AUSTEDO …
Nov 7, 2025 · Teva Pharmaceuticals presented new findings from the IMPACT-TD Registry indicating that treatment with AUSTEDO and AUSTEDO XR significantly improved the lives of …
AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR ...
Nov 7, 2025 · The findings demonstrate that treatment with AUSTEDO (deutetrabenazine) tablets or AUSTEDO XR (deutetrabenazine) extended-release tablets for tardive dyskinesia (TD) led …
Austedo XR Ratings & Reviews by Doctors | Uses & Side Effects
Patients face significant access challenges with Austedo XR due to high costs and insurance problems, which contribute to adherence variability and can hinder consistent treatment across …
Patients Taking AUSTEDO XR® (deutetrabenazine) extended …
Patients taking AUSTEDO XR reported increased social and emotional well-being as a result of movement reduction, and high overall satisfaction with AUSTEDO XR. The data were …
Reported Saturday, Teva Reports Patients With Tardive Dyskinesia …
Sep 22, 2025 · Of the 209 patients with tardive dyskinesia (TD) that were surveyed, >94% reported movement improvement once treated with AUSTEDO XR® (deutetrabenazine) …
Insights into Tardive Dyskinesia and Chorea Treatment with Austedo …
Nov 7, 2024 · The majority of people with TD or chorea associated with Huntington disease (HD) who were treated with Austedo XR (deutetrabenazine; Teva Neuroscience, Kansas City, MO) …
Study Explores Tardive Dyskinesia Outcomes With …
Nov 12, 2024 · It demonstrates real-world treatment patterns and outcomes with once-daily Austedo XR (deutetrabenazine) extended-release tablets and twice-daily Austedo …
Austedo | European Medicines Agency (EMA)
Overview On 19 June 2025, the Committee for Medicinal Products for Human Use (CHMP), adopted a positive opinion, recommending the granting of a marketing authorisation for the …